How do you pack 20 years of ADC learn­ings in­to one com­pa­ny? Tubu­lis has $63M more to an­swer that

More than two decades have passed since the first an­ti­body-drug con­ju­gate went on the mar­ket. But ac­cord­ing to a biotech start­up out of Ger­many, the space is re­al­ly just be­gin­ning to flour­ish.

And if Tubu­lis gets its way, it will play a big part in de­sign­ing the AD­Cs that will be de­ployed in can­cer treat­ments of to­mor­row.

An­dera Part­ners led a new $63 mil­lion (€60 mil­lion) in­to the com­pa­ny, which brought new in­vestors Evotec and Fund+ in­to the syn­di­cate, join­ing Bay­ern Kap­i­tal, Bio­Med­Part­ners, co­par­i­on, High-Tech Grün­der­fonds, OC­CI­DENT and Sev­en­ture Part­ners.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER